Navigation Links
CoLucid Pharmaceuticals, Inc. announces study data documenting oral efficacy of lasmiditan (COL-144), a selective 5-HT1F receptor agonist, in the treatment of acute migraine attacks
Date:6/9/2010

DURHAM, N.C., June 9 -- CoLucid Pharmaceuticals, Inc., ("CoLucid"), an innovative biotechnology company focusing on therapies for central nervous system disorders, today announced that its investigational first-in-class Neurally Acting Anti-Migraine Agent (NAAMA), lasmiditan (also known as COL-144), a selective 5-HT1F receptor agonist, was effective when given orally to treat acute migraine attacks, as documented in a Phase IIb study. Results of this study will allow the selection of doses for pivotal Phase III studies of lasmiditan in the acute treatment of migraine, scheduled to begin in fourth quarter this year.

"There is a high unmet need for novel migraine treatments that are effective and safe," said James F. White, Ph.D., President and Chief Executive Officer of CoLucid. "Currently available drugs have varying efficacy and side effects that limit their use in patients. Lasmiditan with its exciting new mechanism of action has the potential to address these patient needs."

In the recently completed double blind, randomized, placebo-controlled parallel group dose-ranging study conducted in five European countries, 391 patients treated a single migraine attack with one of four doses of lasmiditan or placebo. The Phase IIb study met its primary endpoint, showing a highly significant correlation between dose and headache relief at two hours. Individual doses showed significant benefit compared to the placebo from as early as 30 minutes after treatment. Lasmiditan also provided significant relief of other migraine symptoms, as measured in the study, including nausea, photophobia and phonophobia.

Dizziness and fatigue were the most common adverse events reported in the study. No clinically significant adverse effects were identified in either the laboratory parameters or electrocardiography (ECGs). Cardiovascular adverse events, including chest symptoms experienced with the current migraine medication group known as triptans, were rare and occurred with similar frequency in the placebo and active treatment groups.

The investigators intend to submit a complete Phase IIb data analysis for peer-review publication or presentation.


'/>"/>

Contact: Shirley Chow
Shirley.chow@porternovelli.com
212-601-8308
Porter Novelli
Source:Eurekalert

Related biology news :

1. Biostar Pharmaceuticals, Inc. Receives New Advertising Approval from Shaanxi SFDA for Marketing Xin Aoxing Capsule
2. Selexis Announces Advanced Approach to Maximize Power of Genetic Elements for Rapid Development of High Performance Cell Lines
3. LaserCard Corporation Announces Expansion of Middle East Project
4. BIO-key(R) Announces Contracts for New Criminal Justice Data Sharing Solution
5. Balzan Foundation announces 2007 winners
6. The American Society of Plant Biologists announces 2007 awards
7. ASPB announces Summer Undergraduate Research Fellowship 2007 recipients
8. NIST announces 56 new awards for innovative technology research and development
9. Titanium Group Announces Contract With Haitong Securities
10. Measurement Specialties, Inc. Announces Impact of German Business Tax Reform 2008 Resulting in Lower Combined German Tax Rate - Impacts 2Q08 Reported Financial Results
11. FIJI Water announces sustainable growth initiative with commitment to help mitigate climate change
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... PHILADELPHIA , Jan. 24, 2017  It ... a baby,s sock that monitors vital signs and ... instance, an infant,s oxygen saturation level drops. But ... undue alarm to parents, with no evidence of ... "These devices are marketed aggressively to parents of ...
(Date:1/19/2017)... Jan. 19, 2017 Sensory Inc ... and security for consumer electronics, and i ... systems and cybersecurity solutions, today announced a global ... financial institutions worldwide to bolster security of data ... secure user authentication platforms they offer, innerCore now ...
(Date:1/12/2017)... DIEGO , Jan. 12, 2017  Trovagene, Inc. ... tumor DNA (ctDNA) technologies, today announced that it has ... Europe and the Middle East ... tests.  This milestone marks the first wave of international ... for urine and blood samples. The initial ...
Breaking Biology News(10 mins):
(Date:2/20/2017)... ... February 20, 2017 , ... USARAD ... company announces at HIMSS 2017 Annual Conference (Orlando, FL) a world-wide distribution ... a global cloud-based sharing and collaboration platform as part of the Siemens ...
(Date:2/20/2017)... ORLANDO, Fla. , Feb. 20, 2017 /PRNewswire/ ... (HIMSS) conference in Orlando , ... new offerings, collaborators and clients. IBM Chairman, President ... the HIMSS17 opening keynote address today from 8:30-10 ... www.ibm.com/watson/health , and ibm.com/industries/healthcare. Her remarks examine ...
(Date:2/18/2017)... (PRWEB) , ... February 17, 2017 , ... ... and Marrow Transplantation (ASBMT) and the Center for International Blood & Marrow Transplant ... Center in Orlando, Fla. , The combined scientific sessions offer investigators, ...
(Date:2/17/2017)... Feb. 17, 2017  BioGenex, a global leader ... of a novel system for quantitative immunohistochemistry (IHC). ... University of Rochester (NY, USA) and Konica-Minolta Inc. ... system is able to accurately quantify the expression ... epidermal growth factor receptor-2) in clinical samples. Quantitative ...
Breaking Biology Technology: